Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China

Abstract

Aims: To investigate the distribution of epidermal growth factor receptor (EGFR) mutations, and explore any relationships with clinical characteristics in non-small-cell lung carcinoma (NSCLC) patients. Materials and Methods: EGFR mutations were assessed by ADx-ARMS in 261 NSCLC patients from West China Hospital of Sichuan University. Relationships between EGFR mutation and clinical characteristics were analyzed by SPSS. Results: The EGFR mutation rate was 48.7% (127/261), 19-del and L858R mutations occurred predominantly, accounting for 33.1% and 40.9%, respectively, in mutated cases. Moreover, 10.2% patients were found to carry double mutations. EGFR mutations occurred more frequently in women (57.5%) than in men (41.8%) (P=0.01), and were more frequent in non-smokers (61.2%) than in former or current smokers (31.2%) (P<0.00). In addition, they were more common in adenocarcinomas (52.8%) and adenosquamous carcinomas (42.8%) than in squamous cell carcinomas (14.8%) (p<0.00). However, only smoking history and pathological types, rather than gender, proved to be associated with EGFR mutations on multivariate logistic regression analysis. No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) -19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas. Conclusions: The EGFR mutation rate was 48.7% in NSCLCs in Southwest China, so that nearly 40% patients might benefit from targeted therapies. Smoking status and pathological types were independent predictors of EGFR mutation, while EGFR mutation type was related to only pathological type, rather than smoking status.

miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1

“…Currently, surgical resection combined with chemotherapy and radiotherapy is still the main means of clinical treatment for lung cancer. However, the patients have poor prognosis and 5-year survival rate is ~15% (5). Metastasis is one of the major causes of death in patients with lung cancer.…”

FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer

“…To our knowledge, this is the first study investigating a possible correlation between FGFR mutation status and smoking in lung cancer although such a correlation has been previously demonstrated for other tyrosine kinase receptors, such as EGFR, in lung adenocarcinoma. 44 However, the mechanisms by which smoking status contribute to tyrosine kinase receptors mutation is still largely unknown. Tumors with more advanced TNM stages or with lymph node metastasis were found to exhibit a higher frequency of either FGFR somatic or germline mutation.…”

Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS‐G12D mutation and P53 knockout

“…Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer and includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma . Adenocarcinoma is the most common type of NSCLC, now accounting for about 40% of all lung cancer cases . Genetic alterations in non‐small cell lung cancer (NSCLC) have been identified in recent years.…”

“…2 Adenocarcinoma is the most common type of NSCLC, now accounting for about 40% of all lung cancer cases. 3 Genetic alterations in non-small cell lung cancer (NSCLC) have been identified in recent years. Kristen rat sarcoma viral oncogene (KRAS), epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the most commonly altered oncogenes by acting as tumour genomic drivers.…”